A Study of SGN-CD228A in Advanced Solid Tumors

NCT04042480 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

88

Enrollment

INDUSTRY

Sponsor class

Stopped Study closed due to portfolio prioritization

Conditions

Cutaneous Melanoma
Pleural Mesothelioma
HER2 Negative Breast Neoplasms
Non-small Cell Lung Cancer
Colorectal Cancer
Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: SGN-CD228A

Sponsor

Seagen Inc.